• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依诺肝素低分子量肝素：其在全髋关节置换术后预防深静脉血栓形成中的应用。

Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement.

作者信息

Planes A, Vochelle N, Ferru J, Przyrowski D, Clerc J, Fagola M, Planes M

出版信息

Haemostasis. 1986;16(2):152-8. doi: 10.1159/000215285.

DOI:10.1159/000215285
PMID:3710293
Abstract

UNLABELLED

The effect of Enoxaparin in the prevention of thromboembolism after total hip prosthesis has been controlled by phlebography. 228 consecutives patients were studied with 4 dose regimens: 60 mg once a day, 40 mg once a day, and 30 and 20 mg twice a day.

CONCLUSIONS

a total dose of 40 mg once a day or twice a day gives a rate of postoperative thrombosis of 8%.

摘要

未标记

依诺肝素预防全髋关节置换术后血栓栓塞的效果已通过静脉造影进行了对照研究。对228例连续患者采用4种剂量方案进行了研究：每日1次60毫克、每日1次40毫克以及每日2次30毫克和20毫克。

结论

每日1次或每日2次总剂量40毫克时，术后血栓形成率为8%。

相似文献

1
Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement.依诺肝素低分子量肝素：其在全髋关节置换术后预防深静脉血栓形成中的应用。
Haemostasis. 1986;16(2):152-8. doi: 10.1159/000215285.
2
A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.低分子量肝素与双氢麦角胺固定剂量组合对比调整剂量普通肝素预防全髋关节置换术后深静脉血栓形成的研究
Thromb Haemost. 1996 Feb;75(2):246-50.
3
Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.全髋关节置换术后深静脉血栓形成和肺栓塞的预防。低分子量肝素与普通肝素的比较。
J Bone Joint Surg Am. 1991 Apr;73(4):484-93.
4
Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement.低分子量肝素（依诺肝素）与普通肝素在髋关节置换术患者预防深静脉血栓形成和肺栓塞中的比较。
Ann Chir Gynaecol. 1995;84(1):85-90.
5
Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.低分子量肝素预防全髋关节置换患者深静脉血栓形成。一项随机试验。德国髋关节置换试验（GHAT）组。
Arch Orthop Trauma Surg. 1992;111(2):110-20. doi: 10.1007/BF00443477.
6
The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement.
Thromb Haemost. 1989 Nov 24;62(3):940-4.
7
Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.全髋关节置换术后静脉血栓形成的预防：一项比较普通肝素与低分子肝素在全髋关节置换患者中应用的随机试验
Thromb Haemost. 1988 Dec 22;60(3):407-10.
8
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.髋关节置换术后深静脉血栓形成的预防：普通肝素与低分子量肝素的随机对照比较。
BMJ. 1991 Sep 7;303(6802):543-8. doi: 10.1136/bmj.303.6802.543.
9
Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.低分子量肝素（依诺肝素）用于全髋关节置换术后预防静脉血栓栓塞
N Engl J Med. 1996 Sep 5;335(10):696-700. doi: 10.1056/NEJM199609053351002.
10
Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.使用低分子量肝素依诺肝素和普通肝素预防择期髋关节置换术后深静脉血栓形成。一项比较疗效和安全性的临床试验。依诺肝素临床试验组。
J Bone Joint Surg Am. 1994 Jan;76(1):3-14. doi: 10.2106/00004623-199401000-00002.

引用本文的文献

1
Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.辅助药物治疗：聚焦于低分子量肝素的研发。
J Thromb Thrombolysis. 1997;4(2):197-205. doi: 10.1023/a:1008870228789.
2
New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.新型溶栓剂、抗凝剂和血小板拮抗剂：临床实践的未来。
J Thromb Thrombolysis. 1999 Apr;7(2):195-220. doi: 10.1023/a:1008845822884.
3
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.
剂量调整的肝素治疗深静脉血栓形成：普通肝素与低分子量肝素的比较
Eur J Clin Pharmacol. 1990;39(2):107-12. doi: 10.1007/BF00280041.
4
Orthopaedic surgeons and thromboprophylaxis.骨科外科医生与血栓预防
BMJ. 1991 Sep 7;303(6802):549-50. doi: 10.1136/bmj.303.6802.549.